At a Glance
| Indication | Acute postsurgical pain |
| Drug | EXPAREL and ZILRETTA |
| Company | Viatris Inc. |
| Category | Corporate & Strategic |
| Sub Category | Acquisition Announced |
| Therapeutic Area | Others |
| Deal Value | $1.65 billion |
| Per Share Price | $36.50 |
| Target Company | Pacira BioSciences, Inc. |
| Acquired Products | EXPAREL, ZILRETTA |
| Expected Closing Date | End of 2026 |
| Pacira LTM Revenue | $746 million |
| Pacira LTM Adjusted EBITDA | $177 million |
| Deal Type | Acquisition |
| Viatris Financial Advisor | Morgan Stanley & Co. LLC, Centerview Partners LLC |
| Pacira Financial Advisor | Goldman Sachs & Co. LLC |
Viatris Acquires Pacira BioSciences for $1.65 Billion
Viatris Inc. has entered a definitive agreement to acquire Pacira BioSciences, Inc. for an aggregate equity value of $1.65 billion, paying $36.50 per share in cash. This acquisition aims to advance Viatris' innovative medicines strategy and establish it as a leader in non-opioid pain therapies. Pacira brings two established, high-margin, patent-protected U.S. products: EXPAREL for acute postsurgical pain and ZILRETTA for osteoarthritis knee pain. The deal, unanimously approved by both boards, is expected to close by the end of 2026 and be immediately accretive to Viatris' financial guidance metrics. Pacira generated approximately $746 million in total revenue and $177 million in adjusted EBITDA in the last twelve months ended June 30, 2026.
- The acquisition strategically positions Viatris as a leader in non-opioid pain management, an area with significant unmet patient need. It integrates two key marketed products, EXPAREL for acute postsurgical pain and ZILRETTA for osteoarthritis knee pain, which are highly synergistic with Viatris' existing fast-acting meloxicam opportunity, thereby substantially enhancing its innovative medicines business.
- Viatris will acquire Pacira for $36.50 per share in cash, totaling an aggregate equity value of $1.65 billion. This transaction is anticipated to be immediately accretive to Viatris' financial guidance metrics and will be primarily funded from excess cash, ensuring minimal impact on its gross leverage ratio and reflecting a disciplined capital allocation strategy.
- Beyond the product portfolio, Pacira contributes valuable U.S. innovative commercial, market access, medical affairs, and global R&D capabilities that are highly complementary to Viatris' current infrastructure. Viatris plans to leverage its intellectual property expertise to extend the product lifecycles and expand the global reach of EXPAREL and ZILRETTA across select international markets.
Frequently Asked Questions
What is the strategic significance of non-opioid extended-release pain therapies in the acute postsurgical pain market?
Non-opioid extended-release pain therapies offer a compelling value proposition by providing prolonged analgesia and reducing reliance on opioids post-surgery. These assets are strategically attractive for pharmaceutical companies seeking to diversify portfolios, address unmet needs in pain management, and align with initiatives to combat the opioid crisis. Their ability to improve patient recovery pathways and potentially shorten hospital stays also enhances their market appeal.
How do extended-release local anesthetics, such as EXPAREL, improve patient outcomes in acute postsurgical pain management?
Extended-release local anesthetics deliver sustained pain relief directly at the surgical site, minimizing the need for systemic opioids. This leads to reduced opioid-related side effects, earlier patient mobilization, and improved overall satisfaction with pain control. By providing a foundational analgesic effect, they support multimodal pain management strategies and facilitate a smoother recovery trajectory.
What considerations drive M&A interest in companies developing advanced drug delivery systems for pain management?
M&A interest in advanced drug delivery systems stems from their potential to create differentiated products with enhanced efficacy, safety, or convenience. Proprietary technologies, such as liposomal encapsulation or extended-release formulations, offer strong intellectual property protection and barriers to entry. These innovations can unlock new therapeutic applications, improve patient adherence, and command premium pricing, making them valuable strategic assets.
How do long-acting pain management solutions contribute to addressing the broader opioid crisis in surgical settings?
Long-acting pain management solutions play a crucial role by significantly reducing the initial exposure to opioids in the postsurgical period. By providing effective, sustained analgesia, they decrease the total opioid dose required and mitigate the risk of patients developing persistent opioid use. This approach supports a shift towards non-opioid-centric pain protocols, aligning with public health efforts to curb opioid dependence.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
